

## Pharmacy and Therapeutics (P&T) Committee Meeting Tuesday, February 20<sup>th</sup> 2018, 6:30 p.m. to 8:00 p.m.

### Agenda

Topic:

Presenter:

- |  |   |
|--|---|
| <p><b>1. Welcome</b></p> <ul style="list-style-type: none"> <li>• Call to Order</li> <li>• Roll Call</li> </ul>  | <p>Carl Antolick III, Chair</p>   |
| <p><b>2. Conflict of Interest Statement</b></p>  | <p>Carl Antolick III, Chair</p>   |
| <p><b>3. Minutes from Nov 14, 2018 Meeting*</b></p>  | <p>Carl Antolick III, Chair</p>   |
| <p><b>4. Old Business</b></p> <ul style="list-style-type: none"> <li>• P&amp;T Bylaws</li> <li>• Formulary Development and Management at CVS Caremark</li> <li>• Recap of The Plan's 2018 Formulary Strategy</li> </ul>  | <p>Carl Antolick III, Chair</p>   |
| <p><b>5. Formulary Updates*</b></p> <ul style="list-style-type: none"> <li>• Hyperinflation Exclusions</li> <li>• Tier Changes               <ul style="list-style-type: none"> <li>○ Specialty Designations</li> <li>○ Negative</li> <li>○ Positive</li> </ul> </li> <li>• New Drug Reviews               <ul style="list-style-type: none"> <li>○ Calquence®</li> <li>○ Verzenio™</li> <li>○ Fasentra™</li> <li>○ Hemlibra®</li> </ul> </li> </ul> | <p>Carl Antolick III, Chair</p> <p>Heather Renee Jarnigan, CVS</p> <p>Heather Renee Jarnigan, CVS</p><br><p>Michael Spiritos, MD</p> <p>Michael Spiritos, MD</p> <p>Joseph Shanahan, MD</p> <p>David Konanc, MD</p> |
| <p><b>6. Utilization Management Policy Review*</b></p> <ul style="list-style-type: none"> <li>• New Policies Under Consideration               <ul style="list-style-type: none"> <li>○ PPI Limit Policy</li> <li>○ PPI Post Limit Policy</li> <li>○ Zegerid® Policy</li> <li>○ Uloric® Policy</li> <li>○ Acticlate® Policy</li> </ul> </li> </ul>   | <p>Carl Antolick III, Chair</p> <p>Heather Renee Jarnigan, CVS</p>  |

- Existing Policies
  - 5-HT1 Agonist Policy
  - Migranal® Policy
  - Butorphanol (Stadol®) Policy
  - Lidocaine Policy

Heather Renee Jarnigan, CVS

**7. Adjourn**

Carl Antolick III, Chair

- Next Meeting: *Tuesday May 22, 2017 from 6:30 to 8:00 PM via webinar*